Aurora Cannabis (TSE:ACB) Downgraded to Tender Rating by ATB Cormark Capital Markets

Aurora Cannabis (TSE:ACB) was downgraded by research analysts at ATB Cormark Capital Markets from an “outperform” rating to a “tender” rating in a research note issued to investors on Wednesday,BayStreet.CA reports. They presently have a C$5.60 price target on the stock, down from their previous price target of C$6.50. ATB Cormark Capital Markets’ target price indicates a potential upside of 5.07% from the company’s previous close.

Other equities analysts have also issued research reports about the stock. TD cut their target price on shares of Aurora Cannabis from C$10.00 to C$8.00 and set a “buy” rating for the company in a research report on Friday, June 12th. Canaccord Genuity Group lowered their price target on shares of Aurora Cannabis from C$6.50 to C$5.00 and set a “buy” rating on the stock in a research report on Tuesday, June 30th. Finally, BMO Capital Markets upgraded shares of Aurora Cannabis to a “hold” rating in a research note on Wednesday, August 5th. Two analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of C$6.20.

Aurora Cannabis Stock Performance

Shares of TSE ACB traded up C$0.23 during trading on Wednesday, reaching C$5.33. 459,104 shares of the stock traded hands, compared to its average volume of 425,306. The company has a debt-to-equity ratio of 4.30, a current ratio of 5.36 and a quick ratio of 2.48. The stock has a market capitalization of C$330.23 million, a P/E ratio of -2.75 and a beta of 0.25. Aurora Cannabis has a 52-week low of C$3.59 and a 52-week high of C$9.33. The company has a 50-day moving average of C$4.10 and a 200-day moving average of C$4.58.

Aurora Cannabis (TSE:ACB) last announced its quarterly earnings data on Wednesday, August 5th. The company reported C($0.07) earnings per share for the quarter. Aurora Cannabis had a negative return on equity of 5.21% and a negative net margin of 9.53%.The firm had revenue of C$67.55 million during the quarter. Analysts forecast that Aurora Cannabis will post -0.22 EPS for the current fiscal year.

About Aurora Cannabis

Aurora Cannabis, headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Aurora, CanniMed, Daily Special, MedReleaf, and San Rafael ’71. Although the company primarily operates in Canada, it has expanded internationally through medical cannabis exporting agreements or cultivation facilities in more than 20 countries.